The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GLNCY, GLCNF, RMTI and LOGM
The Klein Law Firm
Aug. 29, 2018
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Glencore plc (OTCMKTS: GLNCY GLCNF) Class Period: September 30, 2016 to July 2, 2018 Lead Plaintiff Deadline: September 7, 2018
The lawsuit alleges that Glencore plc made materially false and/or misleading statements and/or failed to disclose that: (i) Glencore’s conduct would subject it to heightened scrutiny by U.S. and foreign government bodies resulting in investigations into the company’s compliance with money laundering and bribery laws, as well as the Foreign Corrupt Practices Act; and (ii) as a result, defendants’ statements about Glencore’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. On May 18, 2018, Bloomberg reported that the U.K.'s Serious Fraud Office was preparing to open a formal bribery investigation into Glencore. Then on July 3, 2018, Glencore disclosed that the U.S. Department of Justice issued its subsidiary a subpoena to produce documents and other records in connection with its compliance with U.S. money laundering statutes and the Foreign Corrupt Practices Act.
Get additional information about the GLNCY GLCNF lawsuit: http://www.kleinstocklaw.com/pslra-c/glencore-plc?wire=3
Rockwell Medical, Inc. (NASDAQ: RMTI) Class Period: March 16, 2018 to June 26, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that throughout the class period Rockwell Medical, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
Get additional information about the RMTI lawsuit: http://www.kleinstocklaw.com/pslra-c/rockwell-medical-inc?wire=3
LogMeIn, Inc. (NASDAQ: LOGM) Class Period: March 1, 2017 to July 26, 2018 Lead Plaintiff Deadline: October 19, 2018
The lawsuit alleges LogMeIn, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) LogMeIn’s business practices had negatively impacted renewal rates for certain of its services; and (2) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Following this news, shares of LogMeIn fell $26.60 to close at $77.85 per share on July 27, 2018.
Get additional information about the LOGM lawsuit: http://www.kleinstocklaw.com/pslra-c/logmein-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.